The Effect of Ascorbic Acid on the Pharmacokinetics of Levodopa in Elderly Patients with Parkinson Disease
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Levodopa (LD) is one of the most effective drugs for clinical symptoms in patients with Parkinson disease (PD). Most PD patients are advanced in age and may have trouble with LD absorption because aging influences drug absorption processes. Previous reports have indicated that ascorbic acid (AsA) can reduce LD dosage without losing its effectiveness. The current study sought to determine whether AsA affects LD absorption in elderly PD patients. Sixty-seven elderly PD patients took a tablet orally containing 100 mg LD and 10 mg carbidopa following an overnight fast. Plasma LD concentrations were determined at 6 points up to 3 hours, using high-performance liquid chromatography with electrochemical detection. The area under the curve (AUC), peak drug concentration (Cmax), and time to peak drug concentration (Tmax) were calculated. The pharmacokinetic evaluation was repeatedly performed 1 week later in the same way except for adding 200 mg AsA to the tablet. The changes in AUC, Cmax, and Tmax between the tests were evaluated. Significant changes in these parameters were not observed when analyzed using data from all patients. However, significant increases in AUC and Cmax, and a significant reduction in Tmax by adding AsA were observed in 25 patients with baseline AUC < or =2500 ng.hour/mL. In conclusion, AsA can improve LD absorption in elderly PD patients with poor LD bioavailability. LD therapy in combination with AsA may be one of the strategies for PD treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson's disease
Fahn, S. (1992) · Annals of Neurology · doi:10.1002/ana.410320722 · Cited by 211 · cited 1×
“Previously, approximately 2000 to 3000 mg AsA has been used as an antioxidant or a COMT inhibitor.(13,14,16) In the current study, a smaller amount of AsA (200 mg) was combined with LD to eliminate an antioxidant or a COMT-inhibiting effect as much as possible.”
Method
Cited by
Reactive Oxygen Species, Toxicity, Oxidative Stress, and Antioxidants: Chronic Diseases and Aging
Jomova, K., Raptova, R., Alomar, S. Y., Alwasel, S. H., Nepovimova, E., Kuca, K., & Valko, M. (2023) · Archives of Toxicology · doi:10.1007/s00204-023-03562-9 · Cited by 2,638
Vitamin C function in the brain: Vital role of the ascorbate transporter SVCT2
Harrison, F. E., & May, J. M. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.12.018 · Cited by 661
Effects of Vitamin C on health: a review of evidence
Bei, R. (2013) · Frontiers in Bioscience · doi:10.2741/4160 · Cited by 259
Lorente-Picón, M., & Laguna, A. (2021) · Biomolecules · doi:10.3390/biom11030433 · Cited by 69
Metadata
- Authors
- Nagayama, H., Hamamoto, M., Ueda, M., Nito, C., Yamaguchi, H., & Katayama, Y.
- Venue
- Clinical Neuropharmacology
- Published
- 2004-11
- Volume
- 27
- Issue
- 6
- Pages
- 270-273
- ISSN
- 0362-5664 (ISSN-L)
- OpenAlex
- W2025994911
- Cited by
- 79
- References
- 1
- FWCI
- 0.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Effect of Ascorbic Acid on the Pharmacokinetics of Levodopa in Elderly Patients with Parkinson Disease. https://app.cochat.ai/papers/10.1097/01.wnf.0000150865.21759.bc
- The paper
- Nagayama, H., Hamamoto, M., Ueda, M., Nito, C., Yamaguchi, H., & Katayama, Y. (2004). The Effect of Ascorbic Acid on the Pharmacokinetics of Levodopa in Elderly Patients with Parkinson Disease. Clinical Neuropharmacology. https://doi.org/10.1097/01.wnf.0000150865.21759.bc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.